Leadership

Dr. Lennon joined Aadi in October 2023 as President and CEO and member of the board of directors. Dr. Lennon brings more than twenty years of experience leading global biotechnology and pharmaceutical teams, with significant expertise in development and commercialization in oncology and non-oncology mTOR-driven diseases. Dr. Lennon joins Aadi Bioscience following his role as Chief Executive Officer and member of the board of directors at Satellite Bio, a privately held regenerative medicine company. In his prior role he served for 15 years as President, Novartis Gene Therapies and was responsible for development, approval and launch of the blockbuster Zolgensma®, the first systemic gene therapy for the rare disease spinal muscular atrophy approved for use in more than 40 countries. Prior to that, he held leadership roles in Novartis Oncology for the U.S. and Japan regions, having also held key commercial leadership positions in the United States, China and Switzerland while with Novartis. Dr. Lennon started his career as a scientist, cloning a gene important for genomic stability and prevention of cancer. He holds a Ph.D. in Molecular Medicine from Weill Cornell Medical College of Cornell University and a B.A. in Biophysics from Columbia College of Columbia University. After completing his Ph.D., Dr. Lennon joined McKinsey & Company, focusing on R&D strategy and strategic transactions in the pharmaceutical industry.
Scott-Giacobello
Prior to joining Aadi in 2021, Mr. Giacobello's background included fulfilling key financial and operational roles with a long history of leadership in commercial stage growth companies. He played a key role in the buildout of U.S. operations and commercial readiness in his role as CFO at GW Pharmaceuticals, leading the Company's financial strategy and raising more than $620 million ahead of their acquisition by Jazz Pharmaceuticals in 2021. He had previously served as the CFO of Chase Pharmaceuticals prior to their acquisition by Allergan, where he served in executive roles in corporate finance and global research and development.
Loretta-Itri
Dr. Itri joined Aadi in October 2021 as the Chief Medical Officer. She was most recently the CMO at Immunomedics, and before that, Executive Vice President of Global Health Sciences & Regulatory Affairs at The Medicines Company. Previously, she was president of Pharmaceutical Development and CMO at Genta, Inc. Prior to that, Dr. Itri served as Senior Vice President of Medical and Regulatory Affairs at Johnson & Johnson’s Pharmaceutical Research Institute. In addition, she served as SVP of Clinical Affairs and CMO for Ortho Biotech Inc., previously having served as Assistant Vice President of Clinical Development in immunology and oncology at Hoffmann-La Roche. Dr. Itri began her career at Hoffmann-La Roche as Assistant Vice President of Clinical Development in immunology and oncology. Dr. Itri received her MD from New York Medical College, completed her medical residency at SUNY-Stony Brook, and her fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center where she was an adjunct attending physician for more than 15 years. Dr. Itri has served as a member of the National Cancer Institute Board of Scientific Counselors and has published extensively on the development of therapeutic agents.
Steve-Rodin
Mr. Rodin joined Aadi in February 2022 as SVP and General Counsel. He was most recently the Executive Vice President and General Counsel of The Medicines Company, which was acquired by Novartis for $9.7B in January 2020. During his 13-year tenure at The Medicines Company, Steve led or played a substantial role in $750M+ of acquisitions and $650M+ of divestitures. Prior to that, Steve was a corporate attorney at Proskauer Rose LLP in New York. He earned a JD from Vanderbilt University Law School, where he currently sits on the Board of Advisors, and an AB from Georgetown University.
Bryan-Ball
Mr. Ball serves as Aadi’s Chief Quality Officer and SVP Manufacturing Operations, bringing 25 years of experience leading quality, manufacturing and supply chain teams in healthcare regulated industries. Most recently, Mr. Ball served as the CQO and SVP Operations at Intercept Pharmaceuticals, where he oversaw commercial product and prepared the organization to support regulatory submission of pipeline candidates. Prior to Intercept, Mr. Ball served as CQO at Immunomedics, acquired by Gilead Sciences, where he joined after serving as SVP, Global Quality and Safety, Health, and Environmental for Mallinckrodt Pharmaceuticals. Mr. Ball holds an MBA from Westminster College, a Master of Science in Biology from the University of North Carolina and a BS in Biology from Central Michigan University.
Andrew-Kwon
Mr. Kwon brings 13 years of biotech industry experience focused on business development and commercial strategy in oncology and has spent 11 years as a strategy consultant working with top biopharma companies. He was originally trained as a cancer biologist and has held positions as a Research Scientist at Memorial Sloan Kettering Cancer Center and an Associate at Radius Ventures. Andrew received a BS in Biology from Brown University, PhD in Molecular and Medical Pharmacology from University of California Los Angeles, and MBA from Columbia Business School.